Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532250 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.1005156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reducing the environmental impact of healthcare to improve health, sustainability and equity.
BMJ Evid Based Med
January 2025
Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Editorial: 21st meeting of the international council for near infrared spectroscopy - NIR 2023.
Spectrochim Acta A Mol Biomol Spectrosc
January 2025
Institute of Analytical Chemistry and Radiochemistry, University of Innsbruck, Austria. Electronic address:
NIR 2023, or the 21st meeting of The International Council for Near Infrared Spectroscopy (ICNIRS), held in Innsbruck, Austria, in August 2023, was a significant event for the NIR spectroscopy community, bringing together 386 participants from 37 countries. This editorial introduces the Special Issue of Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, featuring nearly 30 articles that represent the topics from the conference. Like the NIR 2023 event itself, this collection highlights advancements in NIR spectroscopy, including fundamental research, instrumentation, and applications.
View Article and Find Full Text PDFCitizen of science.
Science
January 2025
H. Holden Thorp is Editor-in-Chief of the Science journals.
Floyd Bloom, who died on 8 January, was a towering figure in both neuroscience and the scientific community as a whole. As Editor-in-Chief of from 1995 to 2000, he presided over a transformative period in which the journal embraced the digital age, expanding its reach and impact while advocating for open access and the sharing of data. His groundbreaking contributions to neuropharmacology and the understanding of neurotransmitters were only part of his legacy.
View Article and Find Full Text PDFReal-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study.
Dermatol Ther (Heidelb)
January 2025
Department of Clinical and Molecular Sciences-Dermatological Clinic, Università Politecnica Delle Marche, Ancona, Italy.
Introduction: Palmoplantar psoriasis (PPp) has a profound negative impact on patients' quality of life, and it represents a therapeutic challenge, as palms and soles are difficult to treat area. Although the efficacy profile of tildrakizumab has been well evaluated in the literature, data on its use for PPp are still limited. The objective of the study was to evaluate the efficacy and safety of tildrakizumab on moderate-to-severe plaque psoriasis with involvement of the palmoplantar area.
View Article and Find Full Text PDFThe immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
Front Immunol
January 2025
Department of Neurosciences, University of Padua, Padua, Italy.
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!